Swiss biotech company, Engimmune Therapeutics completes its seed financing round raising CHF 15.5 million, co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch. Engimmune Therapeutics is a platform company using cutting-edge technologies
Tags :Lucas Maurer
Versant Ventures debut Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies. Versant has made a USD 50m Series A commitment to Cimeio, which is the most recent start-up to emerge from